Experimental analysis shows that peptide ligands disassemble fibrils into monomers in cell culture, indicating potential for treating parkinson's disease.
Key Points
SVD-1a reduced the toxicity of α-syn fibrils, demonstrating a promising therapeutic approach for parkinson's disease.
The interaction affinity for monomeric α-syn was confirmed to be in the picomolar range, indicating high efficacy of the peptide ligands.
Using mirror-image phage display, peptides were identified that delay aggregation and prevent the formation of α-syn aggregates.
Methods like atomic force microscopy and dynamic light scattering confirmed the disassembly of fibrils into monomers.